Aptevo Therapeutics Inc. (APVO) 10-Year Financial Performance & Capital Metrics

APVO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutAptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Show more

Revenue $0
EBITDA -$24M +14.3%
Net Income -$24M -38.6%
EPS (Diluted) -1747.68 +96.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -284.28% -146.5%
ROIC -2666.4% -244.0%
Debt/Equity 0.97 +120.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 98 (top 2%)
✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-11.6%

EPS CAGR

10Y-

5Y-

3Y-

TTM99.02%

ROCE

10Y Avg-108.51%

5Y Avg-121.79%

3Y Avg-145.7%

Latest-182.22%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	33.6M	36.43M	14.66M	23.07M	0	4.31M	12.29M	3.11M	0	0
Revenue Growth %	-0.26%	0.08%	-0.6%	0.57%	-1%	-	1.85%	-0.75%	-1%	-
Cost of Goods Sold+	16.93M	24.18M	5.01M	11.21M	2.23M	17.85M	0	0	0	352K
COGS % of Revenue	0.5%	0.66%	0.34%	0.49%	-	4.14%	-	-	-	-
Gross Profit+	16.67M	12.25M	9.65M	11.85M	-2.23M	-13.54M	12.29M	3.11M	0	-352K
Gross Margin %	0.5%	0.34%	0.66%	0.51%	-	-3.14%	1%	1%	-	-
Gross Profit Growth %	-0.43%	-0.26%	-0.21%	0.23%	-1.19%	-5.06%	1.91%	-0.75%	-1%	-
Operating Expenses+	77.77M	68.18M	63.6M	63.52M	38.73M	13.95M	33.69M	31.75M	28.88M	24.25M
OpEx % of Revenue	2.31%	1.87%	4.34%	2.75%	-	3.24%	2.74%	10.2%	-	-
Selling, General & Admin	43.04M	38.67M	34.58M	28.13M	13.96M	13.95M	14.7M	13.87M	11.77M	10.22M
SG&A % of Revenue	1.28%	1.06%	2.36%	1.22%	-	3.24%	1.2%	4.46%	-	-
Research & Development	34.73M	29.52M	29.02M	35.38M	24.76M	17.85M	18.99M	17.88M	17.11M	14.38M
R&D % of Revenue	1.03%	0.81%	1.98%	1.53%	-	4.14%	1.55%	5.74%	-	-
Other Operating Expenses	0	0	0	0	0	-17.85M	0	0	0	-352K
Operating Income+	-61.1M	-126.94M	-53.95M	-51.66M	-40.96M	-27.49M	-21.4M	-28.64M	-28.88M	-24.6M
Operating Margin %	-1.82%	-3.48%	-3.68%	-2.24%	-	-6.38%	-1.74%	-9.2%	-	-
Operating Income Growth %	-0.19%	-1.08%	0.58%	0.04%	0.21%	0.33%	0.22%	-0.34%	-0.01%	0.15%
EBITDA+	-58.19M	-125.05M	-51.65M	-49.27M	-38.73M	-26.19M	-20.26M	-27.74M	-28.31M	-24.25M
EBITDA Margin %	-1.73%	-3.43%	-3.52%	-2.14%	-	-6.08%	-1.65%	-8.91%	-	-
EBITDA Growth %	-0.18%	-1.15%	0.59%	0.05%	0.21%	0.32%	0.23%	-0.37%	-0.02%	0.14%
D&A (Non-Cash Add-back)	2.91M	1.9M	2.3M	2.39M	2.23M	1.31M	1.14M	901K	567K	352K
EBIT	-61.1M	-67.76M	-53.95M	-51.66M	-43.06M	-27.49M	-21.4M	-28.64M	-28.88M	-24.13M
Net Interest Income+	0	0	0	0	0	0	0	0	0	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	-237K	-12.64M	-1.94M	-2.02M	-2.1M	-3.43M	-8.01M	35.66M	10.23M	472K
Pretax Income+	-61.34M	-127.75M	-55.89M	-53.69M	-43.06M	-30.92M	-29.41M	7.01M	-18.65M	-24.13M
Pretax Margin %	-1.83%	-3.51%	-3.81%	-2.33%	-	-7.18%	-2.39%	2.25%	-	-
Income Tax+	-2.02M	-15.34M	-23.3M	0	0	0	0	0	0	0
Effective Tax Rate %	0.97%	0.88%	-0.12%	1%	1.04%	0.57%	0.97%	1.14%	0.93%	1%
Net Income+	-59.32M	-112.42M	6.97M	-53.69M	-44.7M	-17.75M	-28.46M	8.03M	-17.41M	-24.13M
Net Margin %	-1.77%	-3.09%	0.48%	-2.33%	-	-4.12%	-2.32%	2.58%	-	-
Net Income Growth %	-0.16%	-0.9%	1.06%	-8.7%	0.17%	0.6%	-0.6%	1.28%	-3.17%	-0.39%
Net Income (Continuing)	-59.32M	-119.89M	-32.59M	-53.69M	-43.06M	-30.92M	-29.41M	7.01M	-18.65M	-24.13M
Discontinued Operations	0	7.48M	39.56M	0	-1.63M	13.17M	951K	1.01M	1.24M	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-999999.00	-999999.00	-976924.00	-999999.00	-999999.00	-308112.00	-197647.00	51217.00	-46335.00	-1747.68
EPS Growth %	-0.16%	-0.89%	0.61%	-0.11%	-5.42%	0.96%	0.36%	1.26%	-1.9%	0.96%
EPS (Basic)	-999999.00	-999999.00	-976924.00	-999999.00	-999999.00	-308112.00	-197647.00	51243.00	-46335.00	-1747.68
Diluted Shares Outstanding	44	44	47	49	6	104	144	157	376	13.81K
Basic Shares Outstanding	44	44	47	49	6	104	144	157	376	13.81K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	35.13M	71.41M	95.08M	48.69M	30M	47.26M	52.57M	27.45M	19.07M	10.66M
Cash & Short-Term Investments	4.64M	54.52M	80.78M	30.64M	12.45M	39.98M	45.04M	22.64M	16.9M	8.71M
Cash Only	4.64M	9.68M	7.09M	30.64M	12.45M	39.98M	45.04M	22.64M	16.9M	8.71M
Short-Term Investments	0	44.85M	73.69M	0	0	0	0	0	0	0
Accounts Receivable	7.83M	307K	2.14M	5.22M	7.02M	2.37M	3.66M	2.5M	0	0
Days Sales Outstanding	85.08	3.08	53.31	82.6	-	200.67	108.8	293.03	-	-
Inventory	20.32M	6.64M	1.03M	1.78M	6.14M	0	0	0	0	0
Days Inventory Outstanding	438.05	100.21	74.89	58.1	1K	-	-	-	-	-
Other Current Assets	0	12.58M	7.11M	4.14M	3.31M	2.69M	2.04M	744K	689K	256K
Total Non-Current Assets+	77.32M	20.44M	21.92M	18.8M	23.41M	6.28M	4.03M	6.76M	5.78M	4.93M
Property, Plant & Equipment	4.18M	5.91M	5.84M	5.2M	7.69M	5.54M	3.96M	6.76M	5.78M	4.93M
Fixed Asset Turnover	8.04x	6.16x	2.51x	4.43x	-	0.78x	3.10x	0.46x	-	-
Goodwill	13.9M	0	0	0	0	0	0	0	0	0
Intangible Assets	59.24M	14.53M	6.08M	5.25M	4.42M	0	0	0	0	0
Long-Term Investments	0	0	-17.37M	7.45M	0	0	0	0	0	0
Other Non-Current Assets	-2.86M	0	10M	8.35M	11.3M	746K	68K	0	0	0
Total Assets+	112.46M	91.86M	117.01M	67.49M	53.41M	53.55M	56.6M	34.22M	24.84M	15.59M
Asset Turnover	0.30x	0.40x	0.13x	0.34x	-	0.08x	0.22x	0.09x	-	-
Asset Growth %	-0.06%	-0.18%	0.27%	-0.42%	-0.21%	0%	0.06%	-0.4%	-0.27%	-0.37%
Total Current Liabilities+	19.94M	19.54M	18.51M	17.61M	38.24M	14.54M	34.76M	8.71M	7.22M	6.21M
Accounts Payable	10.08M	10.52M	7.35M	11.67M	13.04M	0	0	0	0	3.05M
Days Payables Outstanding	217.37	158.76	535.48	379.87	2.13K	-	-	-	-	3.17K
Short-Term Debt	0	0	3.33M	0	19.86M	5M	11.67M	2M	0	0
Deferred Revenue (Current)	1000K	811K	-1000K	0	0	0	0	0	0	0
Other Current Liabilities	2.68M	4.21M	3.2M	2.04M	4.61M	9.54M	23.09M	6.71M	7.22M	3.15M
Current Ratio	1.76x	3.65x	5.14x	2.76x	0.78x	3.25x	1.51x	3.15x	2.64x	1.72x
Quick Ratio	0.74x	3.31x	5.08x	2.66x	0.62x	3.25x	1.51x	3.15x	2.64x	1.72x
Cash Conversion Cycle	305.76	-55.47	-407.27	-239.18	-	-	-	-	-	-
Total Non-Current Liabilities+	3.9M	21.75M	16.46M	19.48M	3.33M	22.41M	20.63M	7.54M	5.4M	4.63M
Long-Term Debt	0	18.38M	15.73M	19.28M	0	20.05M	3.71M	1.46M	0	0
Capital Lease Obligations	0	0	0	0	3.33M	2.36M	1.34M	6.08M	5.4M	4.63M
Deferred Tax Liabilities	506K	0	-224K	0	0	0	0	0	0	0
Other Non-Current Liabilities	71K	469K	734K	200K	0	0	15.58M	0	0	0
Total Liabilities	23.84M	41.29M	34.97M	37.09M	41.57M	36.95M	55.38M	16.24M	12.62M	10.84M
Total Debt+	0	18.38M	19.06M	19.28M	23.19M	27.41M	16.71M	9.54M	5.4M	4.63M
Net Debt	-4.64M	8.71M	11.97M	-11.36M	10.74M	-12.56M	-28.33M	-13.1M	-11.51M	-4.08M
Debt / Equity	-	0.36x	0.23x	0.63x	1.96x	1.65x	13.75x	0.53x	0.44x	0.97x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	88.62M	50.57M	82.03M	30.41M	11.84M	16.59M	1.22M	17.97M	12.22M	4.75M
Equity Growth %	-0.06%	-0.43%	0.62%	-0.63%	-0.61%	0.4%	-0.93%	13.78%	-0.32%	-0.61%
Book Value per Share	999999.00	999999.00	999999.00	616010.60	999999.00	159337.53	8445.68	114686.13	32523.64	344.42
Total Shareholders' Equity	88.62M	50.57M	82.03M	30.41M	11.84M	16.59M	1.22M	17.97M	12.22M	4.75M
Common Stock	320.61M	20K	22K	23K	45K	46K	47K	48K	61K	84K
Retained Earnings	-231.99M	-80.69M	-73.72M	-127.41M	-167.86M	-185.61M	-214.06M	-206.04M	-223.45M	-247.58M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-5.86M	-33K	-105K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-48.76M	-36.86M	-41.57M	-51.42M	-42.38M	-29.32M	-21.68M	-21.02M	-11.73M	-23.79M
Operating CF Margin %	-1.45%	-1.01%	-2.84%	-2.23%	-	-6.8%	-1.76%	-6.75%	-	-
Operating CF Growth %	-0.04%	0.24%	-0.13%	-0.24%	0.18%	0.31%	0.26%	0.03%	0.44%	-1.03%
Net Income	-59.32M	-112.42M	6.97M	-53.69M	-40.45M	-17.75M	-28.46M	8.03M	-17.41M	-24.13M
Depreciation & Amortization	2.91M	3.36M	3.13M	2.39M	2.23M	1.31M	1.14M	901K	567K	352K
Stock-Based Compensation	1.11M	3.81M	4.88M	2.14M	1.6M	1.25M	1.64M	1.8M	2.19M	1.07M
Deferred Taxes	-1.36M	71.21M	-2K	0	0	0	4K	0	0	0
Other Non-Cash Items	3.69M	-16.66M	-52.06M	988K	-3.58M	-12.43M	6.64M	-33.9M	10K	0
Working Capital Changes	4.21M	13.83M	-4.5M	-3.25M	-2.19M	-1.7M	-2.65M	2.14M	2.91M	-1.08M
Change in Receivables	3.88M	1.97M	-1.83M	-3.08M	0	-2.37M	-1.29M	1.16M	2.5M	0
Change in Inventory	-2.7M	13.68M	-567K	-757K	-4.35M	0	1.29M	-1.16M	0	0
Change in Payables	-1.67M	2.48M	195K	1.28M	-2.7M	0	-1.92M	-394K	518K	-1.02M
Cash from Investing+	-1.53M	-47.39M	29.46M	72.8M	4.1M	28.03M	-713K	-29K	0	0
Capital Expenditures	-1.53M	-2.51M	-1.4M	-976K	-153K	-88K	-713K	-29K	0	0
CapEx % of Revenue	0.05%	0.07%	0.1%	0.04%	-	0.02%	0.06%	0.01%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-44.88M	30.86M	73.77M	0	28.12M	0	0	0	0
Cash from Financing+	51.33M	89.3M	9.53M	-787K	20.15M	23.87M	26.16M	-2.62M	6M	15.6M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	51.33M	71.24M	19.53M	-1.41M	-58K	21.26M	26.48M	2.72M	3.04M	5.56M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-50.29M	-39.37M	-42.98M	-52.4M	-42.54M	-29.41M	-22.39M	-21.05M	-11.73M	-23.79M
FCF Margin %	-1.5%	-1.08%	-2.93%	-2.27%	-	-6.82%	-1.82%	-6.76%	-	-
FCF Growth %	-0.05%	0.22%	-0.09%	-0.22%	0.19%	0.31%	0.24%	0.06%	0.44%	-1.03%
FCF per Share	-999999.00	-886807.79	-918189.77	-999999.00	-999999.00	-282359.85	-155522.82	-134319.44	-31216.95	-1722.80
FCF Conversion (FCF/Net Income)	0.82x	0.33x	-5.96x	0.96x	0.95x	1.65x	0.76x	-2.62x	0.67x	0.99x
Interest Paid	0	537K	1.78M	0	0	0	0	0	0	0
Taxes Paid	0	162K	1.36M	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-64.75%	-161.53%	10.52%	-95.5%	-211.6%	-124.84%	-319.56%	83.66%	-115.32%	-284.28%
Return on Invested Capital (ROIC)	-52.37%	-132.92%	-52.8%	-68.55%	-147.58%	-154.97%	-	-	-775.18%	-2666.4%
Gross Margin	49.61%	33.63%	65.82%	51.39%	-	-314.3%	100%	100%	-	-
Net Margin	-176.53%	-308.54%	47.57%	-232.75%	-	-411.93%	-231.51%	257.77%	-	-
Debt / Equity	-	0.36x	0.23x	0.63x	1.96x	1.65x	13.75x	0.53x	0.44x	0.97x
FCF Conversion	0.82x	0.33x	-5.96x	0.96x	0.95x	1.65x	0.76x	-2.62x	0.67x	0.99x
Revenue Growth	-26.36%	8.43%	-59.77%	57.37%	-100%	-	185.26%	-74.67%	-100%	-

Revenue by Segment

	2018	2019
Product	23.07M	32.4M
Product Growth	-	40.46%

Frequently Asked Questions

Growth & Financials

Aptevo Therapeutics Inc. (APVO) grew revenue by 0.0% over the past year. Growth has been modest.

Aptevo Therapeutics Inc. (APVO) reported a net loss of $26.5M for fiscal year 2024.

Dividend & Returns

Aptevo Therapeutics Inc. (APVO) has a return on equity (ROE) of -284.3%. Negative ROE indicates the company is unprofitable.

Aptevo Therapeutics Inc. (APVO) had negative free cash flow of $26.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Aptevo Therapeutics Inc. (APVO) 10-Year Financial Performance & Capital Metrics

APVO • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$24M +14.3%
Net Income -$24M -38.6%
EPS (Diluted) -1747.68 +96.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -284.28% -146.5%
ROIC -2666.4% -244.0%
Debt/Equity 0.97 +120.4%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 98 (top 2%)
✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-11.6%

EPS CAGR

10Y-

5Y-

3Y-

TTM99.02%

ROCE

10Y Avg-108.51%

5Y Avg-121.79%

3Y Avg-145.7%

Latest-182.22%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	33.6M	36.43M	14.66M	23.07M	0	4.31M	12.29M	3.11M	0	0
Revenue Growth %	-0.26%	0.08%	-0.6%	0.57%	-1%	-	1.85%	-0.75%	-1%	-
Cost of Goods Sold+	16.93M	24.18M	5.01M	11.21M	2.23M	17.85M	0	0	0	352K
COGS % of Revenue	0.5%	0.66%	0.34%	0.49%	-	4.14%	-	-	-	-
Gross Profit+	16.67M	12.25M	9.65M	11.85M	-2.23M	-13.54M	12.29M	3.11M	0	-352K
Gross Margin %	0.5%	0.34%	0.66%	0.51%	-	-3.14%	1%	1%	-	-
Gross Profit Growth %	-0.43%	-0.26%	-0.21%	0.23%	-1.19%	-5.06%	1.91%	-0.75%	-1%	-
Operating Expenses+	77.77M	68.18M	63.6M	63.52M	38.73M	13.95M	33.69M	31.75M	28.88M	24.25M
OpEx % of Revenue	2.31%	1.87%	4.34%	2.75%	-	3.24%	2.74%	10.2%	-	-
Selling, General & Admin	43.04M	38.67M	34.58M	28.13M	13.96M	13.95M	14.7M	13.87M	11.77M	10.22M
SG&A % of Revenue	1.28%	1.06%	2.36%	1.22%	-	3.24%	1.2%	4.46%	-	-
Research & Development	34.73M	29.52M	29.02M	35.38M	24.76M	17.85M	18.99M	17.88M	17.11M	14.38M
R&D % of Revenue	1.03%	0.81%	1.98%	1.53%	-	4.14%	1.55%	5.74%	-	-
Other Operating Expenses	0	0	0	0	0	-17.85M	0	0	0	-352K
Operating Income+	-61.1M	-126.94M	-53.95M	-51.66M	-40.96M	-27.49M	-21.4M	-28.64M	-28.88M	-24.6M
Operating Margin %	-1.82%	-3.48%	-3.68%	-2.24%	-	-6.38%	-1.74%	-9.2%	-	-
Operating Income Growth %	-0.19%	-1.08%	0.58%	0.04%	0.21%	0.33%	0.22%	-0.34%	-0.01%	0.15%
EBITDA+	-58.19M	-125.05M	-51.65M	-49.27M	-38.73M	-26.19M	-20.26M	-27.74M	-28.31M	-24.25M
EBITDA Margin %	-1.73%	-3.43%	-3.52%	-2.14%	-	-6.08%	-1.65%	-8.91%	-	-
EBITDA Growth %	-0.18%	-1.15%	0.59%	0.05%	0.21%	0.32%	0.23%	-0.37%	-0.02%	0.14%
D&A (Non-Cash Add-back)	2.91M	1.9M	2.3M	2.39M	2.23M	1.31M	1.14M	901K	567K	352K
EBIT	-61.1M	-67.76M	-53.95M	-51.66M	-43.06M	-27.49M	-21.4M	-28.64M	-28.88M	-24.13M
Net Interest Income+	0	0	0	0	0	0	0	0	0	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	-237K	-12.64M	-1.94M	-2.02M	-2.1M	-3.43M	-8.01M	35.66M	10.23M	472K
Pretax Income+	-61.34M	-127.75M	-55.89M	-53.69M	-43.06M	-30.92M	-29.41M	7.01M	-18.65M	-24.13M
Pretax Margin %	-1.83%	-3.51%	-3.81%	-2.33%	-	-7.18%	-2.39%	2.25%	-	-
Income Tax+	-2.02M	-15.34M	-23.3M	0	0	0	0	0	0	0
Effective Tax Rate %	0.97%	0.88%	-0.12%	1%	1.04%	0.57%	0.97%	1.14%	0.93%	1%
Net Income+	-59.32M	-112.42M	6.97M	-53.69M	-44.7M	-17.75M	-28.46M	8.03M	-17.41M	-24.13M
Net Margin %	-1.77%	-3.09%	0.48%	-2.33%	-	-4.12%	-2.32%	2.58%	-	-
Net Income Growth %	-0.16%	-0.9%	1.06%	-8.7%	0.17%	0.6%	-0.6%	1.28%	-3.17%	-0.39%
Net Income (Continuing)	-59.32M	-119.89M	-32.59M	-53.69M	-43.06M	-30.92M	-29.41M	7.01M	-18.65M	-24.13M
Discontinued Operations	0	7.48M	39.56M	0	-1.63M	13.17M	951K	1.01M	1.24M	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-999999.00	-999999.00	-976924.00	-999999.00	-999999.00	-308112.00	-197647.00	51217.00	-46335.00	-1747.68
EPS Growth %	-0.16%	-0.89%	0.61%	-0.11%	-5.42%	0.96%	0.36%	1.26%	-1.9%	0.96%
EPS (Basic)	-999999.00	-999999.00	-976924.00	-999999.00	-999999.00	-308112.00	-197647.00	51243.00	-46335.00	-1747.68
Diluted Shares Outstanding	44	44	47	49	6	104	144	157	376	13.81K
Basic Shares Outstanding	44	44	47	49	6	104	144	157	376	13.81K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	35.13M	71.41M	95.08M	48.69M	30M	47.26M	52.57M	27.45M	19.07M	10.66M
Cash & Short-Term Investments	4.64M	54.52M	80.78M	30.64M	12.45M	39.98M	45.04M	22.64M	16.9M	8.71M
Cash Only	4.64M	9.68M	7.09M	30.64M	12.45M	39.98M	45.04M	22.64M	16.9M	8.71M
Short-Term Investments	0	44.85M	73.69M	0	0	0	0	0	0	0
Accounts Receivable	7.83M	307K	2.14M	5.22M	7.02M	2.37M	3.66M	2.5M	0	0
Days Sales Outstanding	85.08	3.08	53.31	82.6	-	200.67	108.8	293.03	-	-
Inventory	20.32M	6.64M	1.03M	1.78M	6.14M	0	0	0	0	0
Days Inventory Outstanding	438.05	100.21	74.89	58.1	1K	-	-	-	-	-
Other Current Assets	0	12.58M	7.11M	4.14M	3.31M	2.69M	2.04M	744K	689K	256K
Total Non-Current Assets+	77.32M	20.44M	21.92M	18.8M	23.41M	6.28M	4.03M	6.76M	5.78M	4.93M
Property, Plant & Equipment	4.18M	5.91M	5.84M	5.2M	7.69M	5.54M	3.96M	6.76M	5.78M	4.93M
Fixed Asset Turnover	8.04x	6.16x	2.51x	4.43x	-	0.78x	3.10x	0.46x	-	-
Goodwill	13.9M	0	0	0	0	0	0	0	0	0
Intangible Assets	59.24M	14.53M	6.08M	5.25M	4.42M	0	0	0	0	0
Long-Term Investments	0	0	-17.37M	7.45M	0	0	0	0	0	0
Other Non-Current Assets	-2.86M	0	10M	8.35M	11.3M	746K	68K	0	0	0
Total Assets+	112.46M	91.86M	117.01M	67.49M	53.41M	53.55M	56.6M	34.22M	24.84M	15.59M
Asset Turnover	0.30x	0.40x	0.13x	0.34x	-	0.08x	0.22x	0.09x	-	-
Asset Growth %	-0.06%	-0.18%	0.27%	-0.42%	-0.21%	0%	0.06%	-0.4%	-0.27%	-0.37%
Total Current Liabilities+	19.94M	19.54M	18.51M	17.61M	38.24M	14.54M	34.76M	8.71M	7.22M	6.21M
Accounts Payable	10.08M	10.52M	7.35M	11.67M	13.04M	0	0	0	0	3.05M
Days Payables Outstanding	217.37	158.76	535.48	379.87	2.13K	-	-	-	-	3.17K
Short-Term Debt	0	0	3.33M	0	19.86M	5M	11.67M	2M	0	0
Deferred Revenue (Current)	1000K	811K	-1000K	0	0	0	0	0	0	0
Other Current Liabilities	2.68M	4.21M	3.2M	2.04M	4.61M	9.54M	23.09M	6.71M	7.22M	3.15M
Current Ratio	1.76x	3.65x	5.14x	2.76x	0.78x	3.25x	1.51x	3.15x	2.64x	1.72x
Quick Ratio	0.74x	3.31x	5.08x	2.66x	0.62x	3.25x	1.51x	3.15x	2.64x	1.72x
Cash Conversion Cycle	305.76	-55.47	-407.27	-239.18	-	-	-	-	-	-
Total Non-Current Liabilities+	3.9M	21.75M	16.46M	19.48M	3.33M	22.41M	20.63M	7.54M	5.4M	4.63M
Long-Term Debt	0	18.38M	15.73M	19.28M	0	20.05M	3.71M	1.46M	0	0
Capital Lease Obligations	0	0	0	0	3.33M	2.36M	1.34M	6.08M	5.4M	4.63M
Deferred Tax Liabilities	506K	0	-224K	0	0	0	0	0	0	0
Other Non-Current Liabilities	71K	469K	734K	200K	0	0	15.58M	0	0	0
Total Liabilities	23.84M	41.29M	34.97M	37.09M	41.57M	36.95M	55.38M	16.24M	12.62M	10.84M
Total Debt+	0	18.38M	19.06M	19.28M	23.19M	27.41M	16.71M	9.54M	5.4M	4.63M
Net Debt	-4.64M	8.71M	11.97M	-11.36M	10.74M	-12.56M	-28.33M	-13.1M	-11.51M	-4.08M
Debt / Equity	-	0.36x	0.23x	0.63x	1.96x	1.65x	13.75x	0.53x	0.44x	0.97x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	88.62M	50.57M	82.03M	30.41M	11.84M	16.59M	1.22M	17.97M	12.22M	4.75M
Equity Growth %	-0.06%	-0.43%	0.62%	-0.63%	-0.61%	0.4%	-0.93%	13.78%	-0.32%	-0.61%
Book Value per Share	999999.00	999999.00	999999.00	616010.60	999999.00	159337.53	8445.68	114686.13	32523.64	344.42
Total Shareholders' Equity	88.62M	50.57M	82.03M	30.41M	11.84M	16.59M	1.22M	17.97M	12.22M	4.75M
Common Stock	320.61M	20K	22K	23K	45K	46K	47K	48K	61K	84K
Retained Earnings	-231.99M	-80.69M	-73.72M	-127.41M	-167.86M	-185.61M	-214.06M	-206.04M	-223.45M	-247.58M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-5.86M	-33K	-105K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-48.76M	-36.86M	-41.57M	-51.42M	-42.38M	-29.32M	-21.68M	-21.02M	-11.73M	-23.79M
Operating CF Margin %	-1.45%	-1.01%	-2.84%	-2.23%	-	-6.8%	-1.76%	-6.75%	-	-
Operating CF Growth %	-0.04%	0.24%	-0.13%	-0.24%	0.18%	0.31%	0.26%	0.03%	0.44%	-1.03%
Net Income	-59.32M	-112.42M	6.97M	-53.69M	-40.45M	-17.75M	-28.46M	8.03M	-17.41M	-24.13M
Depreciation & Amortization	2.91M	3.36M	3.13M	2.39M	2.23M	1.31M	1.14M	901K	567K	352K
Stock-Based Compensation	1.11M	3.81M	4.88M	2.14M	1.6M	1.25M	1.64M	1.8M	2.19M	1.07M
Deferred Taxes	-1.36M	71.21M	-2K	0	0	0	4K	0	0	0
Other Non-Cash Items	3.69M	-16.66M	-52.06M	988K	-3.58M	-12.43M	6.64M	-33.9M	10K	0
Working Capital Changes	4.21M	13.83M	-4.5M	-3.25M	-2.19M	-1.7M	-2.65M	2.14M	2.91M	-1.08M
Change in Receivables	3.88M	1.97M	-1.83M	-3.08M	0	-2.37M	-1.29M	1.16M	2.5M	0
Change in Inventory	-2.7M	13.68M	-567K	-757K	-4.35M	0	1.29M	-1.16M	0	0
Change in Payables	-1.67M	2.48M	195K	1.28M	-2.7M	0	-1.92M	-394K	518K	-1.02M
Cash from Investing+	-1.53M	-47.39M	29.46M	72.8M	4.1M	28.03M	-713K	-29K	0	0
Capital Expenditures	-1.53M	-2.51M	-1.4M	-976K	-153K	-88K	-713K	-29K	0	0
CapEx % of Revenue	0.05%	0.07%	0.1%	0.04%	-	0.02%	0.06%	0.01%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-44.88M	30.86M	73.77M	0	28.12M	0	0	0	0
Cash from Financing+	51.33M	89.3M	9.53M	-787K	20.15M	23.87M	26.16M	-2.62M	6M	15.6M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	51.33M	71.24M	19.53M	-1.41M	-58K	21.26M	26.48M	2.72M	3.04M	5.56M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-50.29M	-39.37M	-42.98M	-52.4M	-42.54M	-29.41M	-22.39M	-21.05M	-11.73M	-23.79M
FCF Margin %	-1.5%	-1.08%	-2.93%	-2.27%	-	-6.82%	-1.82%	-6.76%	-	-
FCF Growth %	-0.05%	0.22%	-0.09%	-0.22%	0.19%	0.31%	0.24%	0.06%	0.44%	-1.03%
FCF per Share	-999999.00	-886807.79	-918189.77	-999999.00	-999999.00	-282359.85	-155522.82	-134319.44	-31216.95	-1722.80
FCF Conversion (FCF/Net Income)	0.82x	0.33x	-5.96x	0.96x	0.95x	1.65x	0.76x	-2.62x	0.67x	0.99x
Interest Paid	0	537K	1.78M	0	0	0	0	0	0	0
Taxes Paid	0	162K	1.36M	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-64.75%	-161.53%	10.52%	-95.5%	-211.6%	-124.84%	-319.56%	83.66%	-115.32%	-284.28%
Return on Invested Capital (ROIC)	-52.37%	-132.92%	-52.8%	-68.55%	-147.58%	-154.97%	-	-	-775.18%	-2666.4%
Gross Margin	49.61%	33.63%	65.82%	51.39%	-	-314.3%	100%	100%	-	-
Net Margin	-176.53%	-308.54%	47.57%	-232.75%	-	-411.93%	-231.51%	257.77%	-	-
Debt / Equity	-	0.36x	0.23x	0.63x	1.96x	1.65x	13.75x	0.53x	0.44x	0.97x
FCF Conversion	0.82x	0.33x	-5.96x	0.96x	0.95x	1.65x	0.76x	-2.62x	0.67x	0.99x
Revenue Growth	-26.36%	8.43%	-59.77%	57.37%	-100%	-	185.26%	-74.67%	-100%	-

Revenue by Segment

	2018	2019
Product	23.07M	32.4M
Product Growth	-	40.46%

Frequently Asked Questions

Growth & Financials

Aptevo Therapeutics Inc. (APVO) grew revenue by 0.0% over the past year. Growth has been modest.

Aptevo Therapeutics Inc. (APVO) reported a net loss of $26.5M for fiscal year 2024.

Dividend & Returns

Aptevo Therapeutics Inc. (APVO) has a return on equity (ROE) of -284.3%. Negative ROE indicates the company is unprofitable.

Aptevo Therapeutics Inc. (APVO) had negative free cash flow of $26.1M in fiscal year 2024, likely due to heavy capital investments.